4 Topic Commentaries

ECP 2026: Combined Approach Predicts Metastasis in Prostate Cancer

ECP 2026: Combined Approach Predicts Metastasis in Prostate Cancer

• 

  Tamara Lotan, MD

  Pathology (Urologic Pathology)

  •

  Johns Hopkins Medicine, Brady Urological Institute

  “Most studies have found that PTEN loss is a powerful predictor of which prostate tumors are likely to recur or metastasize,”

  Source
• 

  Cory Abate-Shen, PhD

  Molecular Pharmacology / Urologic Oncology Research

  •

  Columbia University Vagelos College of Physicians and Surgeons

  “If we could know in advance which patients will develop metastases, we could start treatments earlier and treat the cancer more aggressively,”

  Source
• 

  Juan M. Arriaga, PhD

  Molecular Pharmacology / Cancer Genomics

  •

  Columbia University Vagelos College of Physicians and Surgeons

  “The genes in our signature are not only correlated with metastasis, they appear to be driving metastasis,”

  Source
• 

  Aadel A. Chaudhuri, MD, PhD

  Radiation Oncology / Precision Oncology

  •

  Mayo Clinic (Rochester, Minnesota)

  “This suggests that we could identify this highest risk, most deadly form of the disease, and potentially improve these patients' outcomes by trying to turn down this stemness program, which is likely driving lethal prostate cancer,”

  Source